KnotBody Technology

Ion Channel Targeting Antibodies

Iontas has developed a novel antibody format (KnotBodyTM) that facilitates  targeting of ion channels, GPCRs and proteases. These proteins have typically been difficult to target using conventional antibody based technologies.

The KnotBodyTM format combines ion channel modulating functionality of naturally occurring cystine-knot miniproteins (e.g. venom toxins) with the specificity and in vivo half life of monoclonal antibodies. This is achieved by fusing the cystine-knot mini proteins into peripheral CDRs of the antibody VL domain. KnotBodyTM libraries can be generated and screened for enhanced target binding, specificity and functionality. We have also shown that two different targets can be bound by the KnotBodyTM creating a novel bi-specific and bi-valent format with benefits over existing formats.

Benefits

1.

Selectivity

Employing highly selective target binding conferred by toxins

2.

Specificity

Adopting target specificty conferred by antibody components

3.

Selection in Antibody Background

Conveys IgG-like properties on final KnotBodyTM lead molecules

4.

Capability to develop novel bispecific therapeutics

Use of differing functionalties in the heavy and light chain or antibody arms to drive bispecific functionality

Working with IONTAS

We offer the Knotbody technology platform for screening antibodies against ion channels, projects and collaborations are performed within our Cambridge (UK) facilities by expert project teams. We strive to ensure that the project objectives are met or exceeded for delivery of results within agreed timelines. For more information get in touch using the form below or visit our contact page